Runben Biotechnology (SH:603193) Shenwan Hongyuan Securities·2025-10-21 05:44Investment Rating - The report assigns a rating of "Outperform" to the company, indicating a slight downgrade from previous expectations [2][7]. Core Insights - The company reported Q3 2025 earnings that fell below expectations, with revenue of 342 million yuan, a year-on-year increase of 16.67%, and a net profit of 79 million yuan, a year-on-year decrease of 2.89% due to intensified industry competition, seasonal factors, and cost fluctuations [7]. - The sales expense ratio increased significantly due to investments in the Douyin platform, leading to a decline in net profit margin [7]. - The company is expanding its offline channels and deepening partnerships with major retailers, enhancing brand presence and consumer reach [7]. - New product launches targeting youth demographics are being introduced, including a children's sunscreen and an oil-control acne series, aimed at broadening the consumer base [7]. - The company is focused on the domestic personal care market, leveraging its core product categories to drive growth across both online and offline channels [7]. Financial Summary - Total revenue projections for 2025 are estimated at 1,571 million yuan, with a year-on-year growth rate of 19.2% [6]. - The net profit for 2025 is projected to be 315 million yuan, reflecting a growth rate of 4.8% [6]. - The company’s gross margin is expected to remain stable at around 57.7% for 2025, with a return on equity (ROE) of 13.7% [6].